Trials / Active Not Recruiting
Active Not RecruitingNCT00248287
PhII ICb With/Without Erbitux in MBC Pts
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 154 (actual)
- Sponsor
- US Oncology Research · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the objective response rates produced by irinotecan and carboplatin therapy with or without Erbitux in patients with Metastatic Breast Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Irinotecan + Carboplatin | irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle |
| DRUG | irinotecan + Carboplatin + erbitux | irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2 |
Timeline
- Start date
- 2005-07-28
- Primary completion
- 2025-12-01
- Completion
- 2026-12-01
- First posted
- 2005-11-03
- Last updated
- 2025-01-29
- Results posted
- 2016-11-03
Locations
59 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00248287. Inclusion in this directory is not an endorsement.